Cited by 277Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchNeuroinflammation and Neurodegeneration Mechanisms

The DOI matches its Crossref record; 97 of the 97 references it cites were found in a registry or an index.

Impact of Anti-amyloid-β Monoclonal Antibodies on the Pathology and Clinical Profile of Alzheimer’s Disease: A Focus on Aducanumab and Lecanemab

Open access

Shi, Mingchao, Chu, Fengna, Zhu, Feiqi, Zhu, Jie·2022·Frontiers in Aging Neuroscience

DOI 10.3389/fnagi.2022.870517PMC PMC9039457

Open this paper in CoChat — free account Open PDF

Abstract

Alzheimer’s disease (AD) is the most prevalent form of age-related dementia in the world, and its main pathological features consist of amyloid-β (Aβ) plaque deposits and neurofibrillary tangles formed by hyperphosphorylated tau protein. So far, only a few AD treatments approved have been applied in the clinic, but the effects of these drugs are limited only for partial symptomatic relief to patients with AD and are unable to alter AD progression. Later, all efforts for AD treatments with targeting the pathogenic factors were unsuccessful over the past decades, which suggested that the pathogenesis of AD is complex. Recently, disease-modifying therapies (DMTs) that can change the underlying pathophysiology of AD, with anti-Aβ monoclonal antibodies (mabs) (e.g., aducanumab, bapineuzumab, gantenerumab, solanezumab, and lecanemab) have been developed successively and conducted in clinical trials based on the theory that a systemic failure of cell-mediated Aβ clearance contributes to AD occurrence and progression. In the review, we summarized recent studies on the therapeutic effects and clinical trial results of these mabs in patients with AD. Specifically, we focused on the discussion of the impact of aducanumab and lecanemab on AD pathology and clinical profiles. The review provides a possible evidence for applying immunotherapy with anti-Aβ mabs in AD and analyzes lessons learned from these clinical trials in order to further study the therapeutic and adverse effects of these anti-Aβ mabs on AD.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.3389/fnagi.2022.870517

Cites

97 of 97 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

1 retracted

Aducanumab Use in Symptomatic Alzheimer Disease Evidence in Focus [RETIRED]
Day, G. S., Scarmeas, N., Dubinsky, R., Coerver, K., Mostacero, A., West, B., Wessels, S. R., & Armstrong, M. J. (2022) · Neurology · doi:10.1212/wnl.0000000000200176 · Cited by 42
Retracted
Clinical and biomarker changes in dominantly inherited Alzheimer's disease
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814
Neuropathological alterations in Alzheimer disease
Serrano-Pozo, A., Frosch, M. P., Masliah, E., & Hyman, B. T. (2011) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006189 · Cited by 3,345
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059
Untitled work
Bloom (2014) · doi:10.1001/jamaneurol.2013.5847 · Cited by 2,194
Cerebrospinal fluid and plasma biomarkers in Alzheimer disease
Blennow, K., Hampel, H., Weiner, M., & Zetterberg, H. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.4 · Cited by 1,863
Alzheimer's disease
Masters, C. L., Bateman, R., Blennow, K., Rowe, C. C., Sperling, R. A., & Cummings, J. L. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.56 · Cited by 1,853
Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
Doody, R. S., Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1312889 · Cited by 1,668
Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease
DeMattos, R. B., Bales, K. R., Cummins, D. J., Dodart, J.-C., Paul, S. M., & Holtzman, D. M. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.151261398 · Cited by 1,298
Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ 42 in humans
Fagan, A. M., Mintun, M. A., Mach, R. H., Lee, S., Dence, C. S., Shah, A. R., LaRossa, G. N., Spinner, M. L., Klunk, W. E., Mathis, C. A., et al. (2006) · Annals of Neurology · doi:10.1002/ana.20730 · Cited by 1,246
Molecular Structure of β-Amyloid Fibrils in Alzheimer’s Disease Brain Tissue
Lu, J., Qiang, W., Yau, W., Schwieters, C. D., Meredith, S. C., & Tycko, R. (2013) · Cell · doi:10.1016/j.cell.2013.08.035 · Cited by 1,105
Trial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease
Honig, L. S., Vellas, B., Woodward, M., Boada, M., Bullock, R., Borrie, M., Hager, K., Andreasen, N., Scarpini, E., Liu-Seifert, H., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1705971 · Cited by 1,049
Biomarker Modeling of Alzheimer’s Disease
Jack, C. R., & Holtzman, D. M. (2013) · Neuron · doi:10.1016/j.neuron.2013.12.003 · Cited by 1,002
A critical appraisal of amyloid-β-targeting therapies for Alzheimer disease
Panza, F., Lozupone, M., Logroscino, G., & Imbimbo, B. P. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-018-0116-6 · Cited by 965
A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody
Swanson, C. J., Zhang, Y., Dhadda, S., Wang, J., Kaplow, J., Lai, R. Y. K., Lannfelt, L., Bradley, H., Rabe, M., Koyama, A., et al. (2021) · Alzheimer's Research & Therapy · doi:10.1186/s13195-021-00813-8 · Cited by 847
Amyloid-like Aggregates Sequester Numerous Metastable Proteins with Essential Cellular Functions
Olzscha, H., Schermann, S. M., Woerner, A. C., Pinkert, S., Hecht, M. H., Tartaglia, G. G., Vendruscolo, M., Hayer-Hartl, M. K., Hartl, F. U., & Vabulas, R. M. (2011) · Cell · doi:10.1016/j.cell.2010.11.050 · Cited by 696
Cell-to-cell transmission of pathogenic proteins in neurodegenerative diseases
Guo, J. L., & Lee, V. M. Y. (2014) · Nature Medicine · doi:10.1038/nm.3457 · Cited by 641
CSF Aβ 42 levels correlate with amyloid-neuropathology in a population-based autopsy study
Strozyk, D., Blennow, K., White, L. R., & Launer, L. J. (2003) · Neurology · doi:10.1212/01.wnl.0000046581.81650.d0 · Cited by 621
Anti-Amyloid-β Monoclonal Antibodies for Alzheimer’s Disease: Pitfalls and Promise
van Dyck, C. H. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.08.010 · Cited by 568
A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease
for the SCarlet RoAD Investigators, Ostrowitzki, S., Lasser, R. A., Dorflinger, E., Scheltens, P., Barkhof, F., Nikolcheva, T., Ashford, E., Retout, S., Hofmann, C., et al. (2017) · Alzheimer's Research & Therapy · doi:10.1186/s13195-017-0318-y · Cited by 567
Molecular drivers and cortical spread of lateral entorhinal cortex dysfunction in preclinical Alzheimer's disease
Khan, U. A., Liu, L., Provenzano, F. A., Berman, D. E., Profaci, C. P., Sloan, R., Mayeux, R., Duff, K. E., & Small, S. A. (2014) · Nature Neuroscience · doi:10.1038/nn.3606 · Cited by 561
Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE trials as reported by Biogen, December 2019
Knopman, D. S., Jones, D. T., & Greicius, M. D. (2021) · Alzheimer's & Dementia · doi:10.1002/alz.12213 · Cited by 524
Update on Alzheimer’s Disease Therapy and Prevention Strategies
Graham, W. V., Bonito-Oliva, A., & Sakmar, T. P. (2017) · Annual Review of Medicine · doi:10.1146/annurev-med-042915-103753 · Cited by 506
Antibiotics, gut microbiota, and Alzheimer’s disease
Angelucci, F., Cechova, K., Amlerova, J., & Hort, J. (2019) · Journal of Neuroinflammation · doi:10.1186/s12974-019-1494-4 · Cited by 454
Gantenerumab: A Novel Human Anti-Aβ Antibody Demonstrates Sustained Cerebral Amyloid-β Binding and Elicits Cell-Mediated Removal of Human Amyloid-β
Bohrmann, B., Baumann, K., Benz, J., Gerber, F., Huber, W., Knoflach, F., Messer, J., Oroszlan, K., Rauchenberger, R., Richter, W. F., et al. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2011-110977 · Cited by 448
N-methyl D-aspartate (NMDA) receptor antagonists and memantine treatment for Alzheimer’s disease, vascular dementia and Parkinson’s disease
Olivares, D., K. Deshpande, V., Shi, Y., K. Lahiri, D., H. Greig, N., T. Rogers, J., & Huang, X. (2012) · Current Alzheimer Research · doi:10.2174/156720512801322564 · Cited by 407
The role of innate immune responses and neuroinflammation in amyloid accumulation and progression of Alzheimer's disease
Webers, A., Heneka, M. T., & Gleeson, P. A. (2019) · Immunology and Cell Biology · doi:10.1111/imcb.12301 · Cited by 377
High complement levels in astrocyte‐derived exosomes of Alzheimer disease
Goetzl, E. J., Schwartz, J. B., Abner, E. L., Jicha, G. A., & Kapogiannis, D. (2018) · Annals of Neurology · doi:10.1002/ana.25172 · Cited by 373
Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-β
Arndt, J. W., Qian, F., Smith, B. A., Quan, C., Kilambi, K. P., Bush, M. W., Walz, T., Pepinsky, R. B., Bussière, T., Hamann, S., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-24501-0 · Cited by 369
A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer’s disease
Salloway, S., Farlow, M., McDade, E., Clifford, D. B., Wang, G., Llibre-Guerra, J. J., Hitchcock, J. M., Mills, S. L., Santacruz, A. M., Aschenbrenner, A. J., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01369-8 · Cited by 359
Aducanumab, gantenerumab, BAN2401, and ALZ-801—The first wave of amyloid-targeting drugs for Alzheimer’s disease with potential for near term approval
Tolar, M., Abushakra, S., Hey, J. A., Porsteinsson, A., & Sabbagh, M. (2020) · Alzheimer's Research & Therapy · doi:10.1186/s13195-020-00663-w · Cited by 354
Bapineuzumab for mild to moderate Alzheimer’s disease in two global, randomized, phase 3 trials
Vandenberghe, R., Rinne, J. O., Boada, M., Katayama, S., Scheltens, P., Vellas, B., Tuchman, M., Gass, A., Fiebach, J. B., Hill, D., et al. (2016) · Alzheimer's Research & Therapy · doi:10.1186/s13195-016-0189-7 · Cited by 304
Safety and tolerability of BAN2401 - a clinical study in Alzheimer’s disease with a protofibril selective Aβ antibody
Logovinsky, V., Satlin, A., Lai, R. Y. K., Swanson, C. J., Kaplow, J. M., Osswald, G., Basun, H., & Lannfelt, L. (2016) · Alzheimer s Research & Therapy · doi:10.1186/s13195-016-0181-2 · Cited by 302
Aducanumab: First Approval
Dhillon, S. (2021) · Drugs · doi:10.1007/s40265-021-01569-z · Cited by 293
A resurrection of aducanumab for Alzheimer's disease
Schneider, L. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30480-6 · Cited by 286 · cited 2×
“Recently, the significant results demonstrated the modest but greatest efficacy in a phase III trial by aducanumab, supplying important Aβ validation as a therapeutic target (Schneider, 2020).”
Background
Safety and biomarker effects of solanezumab in patients with Alzheimer's disease
Farlow, M. R., Arnold, S. E., van Dyck, C. H., Aisen, P. S. S., Snider, B. J., Porsteinsson, A. P., Friedrich, S. W., Dean, R. A., Gonzales, C., Sethuraman, G., et al. (2012) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2011.09.224 · Cited by 285
The path forward in Alzheimer's disease therapeutics: Reevaluating the amyloid cascade hypothesis
Tolar, M., Abushakra, S., & Sabbagh, M. (2020) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2019.09.075 · Cited by 275
The Murine Version of BAN2401 (mAb158) Selectively Reduces Amyloid-β Protofibrils in Brain and Cerebrospinal Fluid of tg-ArcSwe Mice
Tucker, S., Möller, C., Tegerstedt, K., Lord, A., Laudon, H., Sjödahl, J., Söderberg, L., Spens, E., Sahlin, C., Waara, E. R., et al. (2015) · Journal of Alzheimer’s Disease · doi:10.3233/jad-140741 · Cited by 272 · cited 1×
“It has been evidenced that lecanemab can reduce the pathogenic Aβ, prevent Aβ deposition, and selectively reduce Aβ protofibrils in the brain and CSF of AD animal models (Söllvander et al., 2015; Tucker et al., 2015).”
Background
ABBY
Cummings, J. L., Cohen, S., van Dyck, C. H., Brody, M., Curtis, C. T., Cho, W., Ward, M. E., Friesenhahn, M. J., Rabe, C., Brunstein, F., et al. (2018) · Neurology · doi:10.1212/wnl.0000000000005550 · Cited by 261
Effects of monoclonal antibodies against amyloid-β on clinical and biomarker outcomes and adverse event risks: A systematic review and meta-analysis of phase III RCTs in Alzheimer’s disease
Avgerinos, K. I., Ferrucci, L., & Kapogiannis, D. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101339 · Cited by 247
Florbetapir PET analysis of amyloid-β deposition in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional study
Fleisher, A., Chen, K., Quiroz, Y. T., Jakimovich, L. J., Gomez, M. G., Langois, C. M., Langbaum, J. B. S., Ayutyanont, N., Roontiva, A., Thiyyagura, P., et al. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70227-2 · Cited by 246
Gantenerumab reduces amyloid-β plaques in patients with prodromal to moderate Alzheimer’s disease: a PET substudy interim analysis
Klein, G., Delmar, P., Voyle, N., Rehal, S., Hofmann, C., Abi-Saab, D., Andjelkovic, M., Ristic, S., Wang, G., Bateman, R., et al. (2019) · Alzheimer's Research & Therapy · doi:10.1186/s13195-019-0559-z · Cited by 212
Kinetic fingerprints differentiate the mechanisms of action of anti-Aβ antibodies
Linse, S. S., Scheidt, T., Bernfur, K., Vendruscolo, M., Dobson, C. M., Cohen, S. I. A., Šileikis, E., Lundqvist, M., Qian, F., O’Malley, T. T., et al. (2020) · Nature Structural & Molecular Biology · doi:10.1038/s41594-020-0505-6 · Cited by 199
Aducanumab: evidence from clinical trial data and controversies
Tampi, R. R., Forester, B. P., & Agronin, M. (2021) · Drugs in Context · doi:10.7573/dic.2021-7-3 · Cited by 190
First-in-human, double-blind, placebo-controlled, single-dose escalation study of aducanumab (BIIB037) in mild-to-moderate Alzheimer's disease
Ferrero, J., Williams, L., Stella, H., Leitermann, K., Mikulskis, A., O'Gorman, J., & Sevigny, J. (2016) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2016.06.002 · Cited by 189
Indicators of amyloid burden in a population-based study of cognitively normal elderly
Mielke, M. M., Wiste, H. J., Weigand, S. D., Knopman, D. S., Lowe, V. J., Roberts, R. O., Geda, Y. E., Swenson-Dravis, D. M., Boeve, B. F., Senjem, M. L., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e31826e2696 · Cited by 163
ADCOMS: a composite clinical outcome for prodromal Alzheimer's disease trials
Wang, J., Logovinsky, V., Hendrix, S. B., Stanworth, S. H., Perdomo, C., Xu, L., Dhadda, S., Do, I., Rabe, M., Luthman, J., et al. (2016) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2015-312383 · Cited by 160
Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer’s disease (BLAZE)
Salloway, S., Honigberg, L. A., Cho, W., Ward, M. E., Friesenhahn, M. J., Brunstein, F., Quartino, A. L., Clayton, D., Mortensen, D. L., Bittner, T., et al. (2018) · Alzheimer s Research & Therapy · doi:10.1186/s13195-018-0424-5 · Cited by 156
Epidemiological of and risk factors for Alzheimer's disease: A review
Povová, J., Ambrož, P., Bar, M., Pavuková, V., Šerý, O., Tomášková, H., & Janout, V. (2012) · Biomedical Papers · doi:10.5507/bp.2012.055 · Cited by 143
Immunotherapy for Alzheimer‘s Disease: From Anti-β-Amyloid to Tau-Based Immunization Strategies
Panza, F., Frisardi, V., Solfrizzi, V., Imbimbo, B. P., Logroscino, G., Santamato, A., Greco, A., Seripa, D., & Pilotto, A. (2012) · Immunotherapy · doi:10.2217/imt.11.170 · Cited by 130
Structure of Crenezumab Complex with Aβ Shows Loss of β-Hairpin
Ultsch, M., Li, B., Maurer, T., Mathieu, M., Adolfsson, O., Muhs, A., Pfeifer, A., Pihlgren, M., Bainbridge, T. W., Reichelt, M., et al. (2016) · Scientific Reports · doi:10.1038/srep39374 · Cited by 124
Immunotherapy with Aducanumab Restores Calcium Homeostasis in Tg2576 Mice
Kastanenka, K. V., Bussière, T., Shakerdge, N. B., Qian, F., Weinreb, P. H., Rhodes, K., & Bacskai, B. J. (2016) · Journal of Neuroscience · doi:10.1523/jneurosci.2080-16.2016 · Cited by 111
Effect of Different Anti-Aβ Antibodies on Aβ Fibrillogenesis as Assessed by Atomic Force Microscopy
Legleiter, J. A., Czilli, D. L., Gitter, B. D., Demattos, R. B., Holtzman, D. M., & Kowalewski, T. (2003) · Journal of Molecular Biology · doi:10.1016/j.jmb.2003.11.019 · Cited by 105
A comparative study of the effects of Aducanumab and scanning ultrasound on amyloid plaques and behavior in the APP23 mouse model of Alzheimer disease
Leinenga, G., Koh, W. K., & Götz, J. (2021) · Alzheimer's Research & Therapy · doi:10.1186/s13195-021-00809-4 · Cited by 97
Solanezumab for the treatment of mild-to-moderate Alzheimer’s disease
Imbimbo, B. P., Ottonello, S., Frisardi, V., Solfrizzi, V., Greco, A., Seripa, D., Pilotto, A., & Panza, F. (2012) · Expert Review of Clinical Immunology · doi:10.1586/eci.11.93 · Cited by 93
ENGAGE and EMERGE: Truth and consequences?
Kuller, L. H., & López, O. L. (2021) · Alzheimer s & Dementia · doi:10.1002/alz.12286 · Cited by 90
Clinical Development of Aducanumab, an Anti-Aβ Human Monoclonal Antibody Being Investigated for the Treatment of Early Alzheimer's Disease.
Haeberlein, S. B., O'Gorman, J. T., Chiao, P.-C., Bussière, T., von Rosenstiel, P., Tian, Y., Zhu, Y., von Hehn, C., Gheuens, S., Skordos, L., et al. (2017) · PubMed · doi:10.14283/jpad.2017.39 · Cited by 88
Critical Appraisal of Amyloid Lowering Agents in AD
Decourt, B., Boumelhem, F., Pope, E. D., Shi, J., Mari, Z. K., & Sabbagh, M. N. (2021) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-021-01125-y · Cited by 87
Emerge and Engage topline results: Phase 3 studies of aducanumab in early Alzheimer’s disease: Developments in clinical trials and cognitive assessment
Haeberlein, S. B., von Hehn, C., Tian, Y., Chalkias, S., Muralidharan, K. K., Chen, T., Wu, S., Skordos, L., Nisenbaum, L., Rajagovindan, R., et al. (2020) · Alzheimer's & Dementia · doi:10.1002/alz.047259 · Cited by 81
Alzheimer’s drugs take a new tack
Callaway, E. (2012) · Nature · doi:10.1038/489013a · Cited by 77
Neurodegenerative diseases as proteinopathies-driven immune disorders
Lanuti, P., Ciccocioppo, F., Bologna, G., Ercolino, E., Pierdomenico, L., Simeone, P., Pieragostino, D., Boccio, P. D., Marchisio, M., & Miscia, S. (2019) · Neural Regeneration Research · doi:10.4103/1673-5374.268971 · Cited by 76
CLINICAL EFFECTS OF TRAMIPROSATE IN APOE4/4 HOMOZYGOUS PATIENTS WITH MILD ALZHEIMER’S DISEASE SUGGEST DISEASE MODIFICATION POTENTIAL
Abushakra, S., Porsteinsson, A., Scheltens, P., Sadowsky, C., Vellas, B., Cummings, J., Gauthier, S., Hey, J. A., Power, A., Wang, P., et al. (2017) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2017.26 · Cited by 75
Pyroglutamation of amyloid-βx-42 (Aβx-42) followed by Aβ1–40 deposition underlies plaque polymorphism in progressing Alzheimer’s disease pathology
Michno, W., Nyström, S., Wehrli, P. M., Lashley, T., Brinkmalm, G., Guérard, L., Syvänen, S., Sehlin, D., Kaya, I., Brinet, D., et al. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.006604 · Cited by 75
Stopping Alzheimer's Before It Starts
Miller, G. (2012) · Science · doi:10.1126/science.337.6096.790 · Cited by 73
Innate Immunity in Alzheimer’s Disease: A Complex Affair
Guillot‐Sestier, M., & Town, T. (2013) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527311312050008 · Cited by 72
Impact of Reference and Target Region Selection on Amyloid PET SUV Ratios in the Phase 1b PRIME Study of Aducanumab
Chiao, P., Bedell, B. J., Avants, B., Zijdenbos, A. P., Grand’Maison, M., O’Neill, P., O'Gorman, J. T., Chen, T., & Koeppe, R. A. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.209130 · Cited by 68
Safety, Tolerability, and Pharmacokinetics of Crenezumab in Patients with Mild-to-Moderate Alzheimer’s Disease Treated with Escalating Doses for up to 133 Weeks
Guthrie, H., Honig, L. S., Lin, H. H., Sink, K. M., Blondeau, K., Quartino, A. L., Dolton, M. J., Carrasco‐Triguero, M., Lian, Q., Bittner, T., et al. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200134 · Cited by 67
CLINICAL BENEFITS OF TRAMIPROSATE IN ALZHEIMER’S DISEASE ARE ASSOCIATED WITH HIGHER NUMBER OF APOE4 ALLELES: THE “APOE4 GENE-DOSE EFFECT”
Abushakra, S. R., Porsteinsson, A. P., Vellas, B. J., Cummings, J. L., Gauthier, S. G., Hey, J. A., Power, A., Hendrix, S. B., Wang, P., Shen, L., et al. (2016) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2016.115 · Cited by 65
Thirty-Six-Month Amyloid Positron Emission Tomography Results Show Continued Reduction in Amyloid Burden with Subcutaneous Gantenerumab
Klein, G., Delmar, P., Kerchner, G. A., Hofmann, C., Abi‐Saab, D., Davis, A., Voyle, N., Baudler, M., da Fontoura, P. P., & Doody, R. S. (2021) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2020.68 · Cited by 63
Sink Hypothesis and Therapeutic Strategies for Attenuating Aβ Levels
Zhang, Y., & Lee, D. H. S. (2011) · The Neuroscientist · doi:10.1177/1073858410381532 · Cited by 61
Increased Number of Plasma B Cells Producing Autoantibodies Against Aβ 42 Protofibrils in Alzheimer’s Disease
Söllvander, S., Ekholm-Pettersson, F., Brundin, R.-M., Westman, G., Kilander, L., Paulie, S., Lannfelt, L., & Sehlin, D. (2015) · Journal of Alzheimer’s Disease · doi:10.3233/jad-150236 · Cited by 60
Emerging Proof of Protein Misfolding and Interactions in Multifactorial Alzheimer's Disease
Uddin, M. S., Mamun, A. A., Rahman, M. A., Behl, T., Perveen, A., Hafeez, A., Bin-Jumah, M. N., Abdel‐Daim, M. M., & Ashraf, G. M. (2020) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026620666200601161703 · Cited by 59
Target Dysbiosis of Gut Microbes as a Future Therapeutic Manipulation in Alzheimer’s Disease
Zhu, F., Li, C., Chu, F., Tian, X., & Zhu, J. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.544235 · Cited by 59
Self-citation
Lessons Learnt from the Second Generation of Anti-Amyloid Monoclonal Antibodies Clinical Trials
Kwan, A. T. H., Arfaie, S., Therriault, J., Rosa‐Neto, P., & Gauthier, S. G. (2020) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000511506 · Cited by 59
Passive antiamyloid immunotherapy for Alzheimer's disease
Loureiro, J. C., Pais, M. V., Stella, F., Radanovic, M., Teixeira, A. L., Forlenza, O. V., & de Souza, L. C. (2020) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000587 · Cited by 57
Predicted Lifetime Health Outcomes for Aducanumab in Patients with Early Alzheimer’s Disease
Herring, W. L., Gould, I. G., Fillit, H. M., Lindgren, P., Forrestal, F., Thompson, R., & Pemberton-Ross, P. J. (2021) · Neurology and Therapy · doi:10.1007/s40120-021-00273-0 · Cited by 57
Alzheimer's and Aducanumab: Unjust Profits and False Hopes
Fleck, L. M. (2021) · The Hastings Center Report · doi:10.1002/hast.1264 · Cited by 53
Aducanumab for Alzheimer's disease: a regulatory perspective.
Nisticò, R., & Borg, J. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105754 · Cited by 52
Profile of gantenerumab and its potential in the treatment of Alzheimer's disease
Nisticò, R., Novakovic, D., Feligioni, M., Scaccianoce, S., Piccinin, S., Mercuri, N. B., Nicoletti, F., Caruso, A., Schepisi, C., & Errico, F. (2013) · Drug Design Development and Therapy · doi:10.2147/dddt.s53401 · Cited by 50
Anti-Neuroinflammatory Potential of Polyphenols by Inhibiting NF-Κb to Halt Alzheimer's Disease
Uddin, M. S., Hasana, S., Ahmad, J., Hossain, M. F., Rahman, M. M., Behl, T., Rauf, A., Ahmad, A., Hafeez, A., Perveen, A., et al. (2021) · Current Pharmaceutical Design · doi:10.2174/1381612826666201118092422 · Cited by 49
Pharmacokinetics and pharmacodynamic effect of crenezumab on plasma and cerebrospinal fluid beta-amyloid in patients with mild-to-moderate Alzheimer’s disease
Yoshida, K. J., Moein, A., Bittner, T., Ostrowitzki, S., Lin, H. H., Honigberg, L. A., Jin, J. Y., & Quartino, A. L. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-0580-2 · Cited by 48
Anti-Aβ Antibody Aducanumab Regulates the Proteome of Senile Plaques and Closely Surrounding Tissue in a Transgenic Mouse Model of Alzheimer’s Disease
Bastrup, J., Hansen, K. H., Poulsen, T. B. G., Kastaniegaard, K., Asuni, A. A., Christensen, S., Belling, D., Helboe, L., Stensballe, A., & Volbracht, C. (2021) · Journal of Alzheimer's Disease · doi:10.3233/jad-200715 · Cited by 46
Passive Immunotherapies Targeting Amyloid Beta and Tau Oligomers in Alzheimer’s Disease
Zanden, C. M. V., & Chi, E. Y. (2019) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2019.10.024 · Cited by 40
N‐terminal heterogeneity of parenchymal and vascular amyloid‐β deposits in Alzheimer’s disease
Zampar, S., Klafki, H., Sritharen, K., Bayer, T. A., Wiltfang, J., Rostagno, A. A., Ghiso, J. A., Miles, L. A., & Wirths, O. (2020) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12637 · Cited by 36
Elevated soluble amyloid beta protofibrils in Down syndrome and Alzheimer's disease
Johannesson, M., Sahlin, C., Söderberg, L., Basun, H., Fälting, J. M., Möller, C., Zachrisson, O., Sunnemark, D., Svensson, A., Odergren, T., et al. (2021) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2021.103641 · Cited by 35
Safety, Tolerability, and Pharmacokinetics of High‐Volume Subcutaneous Crenezumab, With and Without Recombinant Human Hyaluronidase in Healthy Volunteers
Dolton, M. J., Chesterman, A., Moein, A., Sink, K. M., Waitz, A., Blondeau, K., Kerchner, G. A., Hu, N., Brooks, L., Wetzel-Smith, M. K., et al. (2021) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2385 · Cited by 27
Treatment with scFv-h3D6 Prevented Neuronal Loss and Improved Spatial Memory in Young 3xTg-AD Mice by Reducing the Intracellular Amyloid-β Burden
Esquerda-Canals, G., Roda, A. R., Martı́, J., Montoliu‐Gaya, L., Rivera-Hernández, G., & Villegas, S. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190484 · Cited by 26
Progression of Alzheimer's disease and effect of scFv‐h3D6 immunotherapy in the 3xTg‐AD mouse model: An in vivo longitudinal study using Magnetic Resonance Imaging and Spectroscopy
Güell‐Bosch, J., Lope‐Piedrafita, S., Esquerda‐Canals, G., Montoliu‐Gaya, L., & Villegas, S. (2020) · NMR in Biomedicine · doi:10.1002/nbm.4263 · Cited by 21
Can Anti–β-amyloid Monoclonal Antibodies Work in Autosomal Dominant Alzheimer Disease?
Imbimbo, B. P., Lucca, U., & Watling, M. I. L. (2020) · Neurology Genetics · doi:10.1212/nxg.0000000000000535 · Cited by 15
Anti-Amyloid-β Immunotherapy for Alzheimer’s Disease
Crehan, H., & Lemere, C. A. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802173-6.00007-1 · Cited by 14
Pharmacokinetic parameters and mechanism of action of an efficient anti-Aβ single chain antibody fragment
Esquerda-Canals, G., Martı́, J., & Villegas, S. (2019) · PLoS ONE · doi:10.1371/journal.pone.0217793 · Cited by 12
Persistence Of BAN2401-Mediated Amyloid Reductions Post-treatment: A Preliminary Comparison of Amyloid Status Between the Core Phase of BAN2401-G000-201 and Baseline of the Open-Label Extension Phase in Subjects with Early Alzheimer’s Disease (1330)
Swanson, C. J., Zhang, Y., Dhadda, S., Wang, J., Kaplow, J. M., Bradley, H., Rabe, M. P., Totsuka, K., Lai, R. Y. K., Gordon, R., et al. (2020) · Neurology · doi:10.1212/wnl.94.15_supplement.1330 · Cited by 10
Relationship between CNS and Immunology: Correlation with Psychology
Ashraf, G. M., Azhar, A., Zia, Q., Ali, A., Rehan, M., Owais, M., Alexiou, A. T., Rauf, A., Ganash, M., Kamal, M. A., et al. (2018) · Current Drug Metabolism · doi:10.2174/1389200219666180129142534 · Cited by 9
Prediction of Alzheimer's disease
Alexiou, A. T., Chatzichronis, S., & Ashraf, G. M. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-815854-8.00023-9 · Cited by 6
Solanezumab in‐depth outcomes
Farlow, M. R., Bateman, R. J., Aschenbrenner, A. J., Benzinger, T. L. S., Clifford, D. B., Coalier, K. A., Cruchaga, C., Fagan, A. M., Goate, A., Gordon, B. A., et al. (2020) · Alzheimer s & Dementia · doi:10.1002/alz.038028 · Cited by 5
Higher Dose Gantenerumab leads to Significant Reduction in Amyloid Plaque Burden -Results for the Marguerite and Scarlet Road Open Label Extension Studies (S2.005)
Klein, G., Delmar, P., Hofmann, C., Adjelkovic, M., Abi‐Saab, D., Milosavljevic‐Ristic, S., Baudler, M., Fontura, P., & Doody, R. S. (2018) · Neurology · doi:10.1212/wnl.90.15_supplement.s2.005 · Cited by 4
O1‐02‐04: BASELINE CHARACTERICS FROM A PHASE 3 TRIAL OF CRENEZUMAB IN PRODROMAL TO MILD ALZHEIMER'S DISEASE (CREAD)
Lin, H. H., Ostrowitzki, S., Sink, K. M., Millar, L., Warren, F., Smith, J. P., Schneider, A., Fuji, R. N., Quartino, A. L., Mackey, H. M., et al. (2018) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2018.06.2339 · Cited by 2

Research works printed but not linked: 3

221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer’s Disease (ENGAGE).
221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer’s Disease (EMERGE).
Swanson, 2018, Clinical and biomarker updates from BAN2401 Study 201 in early AD, Proceedings of Clinical Trials on Alzheimer’s Disease Conference

Sorted by citations

Multifunctional nanoparticle-mediated combining therapy for human diseases
Li, X., Peng, X., Zoulikha, M., Boafo, G. F., Magar, K. T., Ju, Y., & He, W. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01668-1 · Cited by 573
Lecanemab in patients with early Alzheimer’s disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study
McDade, E., Cummings, J. L., Dhadda, S., Swanson, C. J., Reyderman, L., Kanekiyo, M., Koyama, A., Irizarry, M. C., Kramer, L. D., & Bateman, R. J. (2022) · Alzheimer s Research & Therapy · doi:10.1186/s13195-022-01124-2 · Cited by 328
Oxidative stress in Alzheimer’s disease: current knowledge of signaling pathways and therapeutics
Dhapola, R., Beura, S. K., Sharma, P., Singh, S. K., & HariKrishnaReddy, D. (2024) · Molecular Biology Reports · doi:10.1007/s11033-023-09021-z · Cited by 288
Alzheimer's disease current therapies, novel drug delivery systems and future directions for better disease management
Singh, B., Day, C. M., Abdella, S., & Garg, S. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.01.047 · Cited by 256
Human Microglia Show Unique Transcriptional Changes in Alzheimer's Disease
Prater, K. E., Green, K. J., Mamde, S., Sun, W., Cochoit, A., Smith, C. L., Chiou, K. L., Heath, L., Rose, S. E., Wiley, J., et al. (2023) · Nature Aging · doi:10.1038/s43587-023-00424-y · Cited by 164

See all 277

Authors: Shi, M., Chu, F., Zhu, F., & Zhu, J.
Affiliations: First Hospital of Jilin University (CN)
Shenzhen University (CN)
Karolinska University Hospital (SE)
Corresponding author: Zhu, Feiqi
Zhu, Jie
ORCID: Shi, Mingchao
Chu, Fengna
Zhu, Feiqi
Zhu, Jie
Venue: Frontiers in Aging Neuroscience
Publisher: Frontiers Media SA
Published: 2022-04-12
Volume: 14
Pages: 870517-870517
ISSN: 1663-4365 (ISSN-L)
DOI: 10.3389/fnagi.2022.870517
PMC: PMC9039457
OpenAlex: W4223533048
Cited by: 275
References: 97
Citations by year: 2026: 28 · 2025: 66 · 2024: 104 · 2023: 68 · 2022: 8
FWCI: 8.46
Type: journal article
Language: en
Open access: gold
doi.org
Licence: cc-by
creativecommons.org/licenses/by/4.0/ (vor)
Locations: Frontiers in Aging Neuroscience (publishedVersion, cc-by)
PubMed Central (publishedVersion, cc-by)
PubMed (publishedVersion)
DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders: People's Government of Jilin Province
Jilin University
Sanming Project of Medicine in Shenzhen (SZSM201801014)
First Hospital of Jilin University
Topics: Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords: Alzheimer's disease, anti-amyloid beta monoclonal antibody, aducanumab, lecanemab, amyloid plaques, disease-modifying therapy, immunotherapy, clinical trial results, adverse effects, amyloid-beta clearance, tau hyperphosphorylation, neurofibrillary tangles

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Impact of Anti-amyloid-β Monoclonal Antibodies on the Pathology and Clinical Profile of Alzheimer’s Disease: A Focus on Aducanumab and Lecanemab

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks